TickerTalks
Browse all tickers →
TickerTalks›$GPCR
GPGPCR

Structure Therapeutics Inc.

$GPCR·$3.1B·Biotechnology·Healthcare
$50.59-2.0%YTD-27.5%1Y+158.5%
Mentions · last 7 days
2026-07-07: 22 posts2026-07-08: 20 posts2026-07-09: 9 posts2026-07-10: 12 posts2026-07-11: 7 posts2026-07-12: 20 posts2026-07-13: 22 posts114+18%
Price updated 6h ago·X counts updated 1d ago
GPGPCR
$GPCRStructure Therapeutics Inc.
$50.59-2.03%114 posts+18%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $GPCR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-07-13

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Structure Therapeutics is the peer-set next-in-line GLP-1 name — Cantor and Piper both bullish on the space.

Structure Therapeutics is a clinical-stage biotech developing GLP-1 and other GPCR-targeting metabolic drugs. This year has been rough (-23.5% YTD) but the 12-month trailing return of +182% reflects the real optionality of the obesity/GLP-1 peer set that also includes Viking Therapeutics, Lilly, and Novo Nordisk.

What's actually here:

  • There is no business to underwrite yet: Q1 revenue was $0 against a $3.07B market cap — the equity is priced entirely on the probability that Structure's oral small-molecule GLP-1 agonist reaches Phase 3 successfully and either commercializes or gets acquired by big pharma.
  • The peer-set framing is real and directionally supported: Cantor and Piper Sandler both reiterated Overweight on Viking Therapeutics, and GPCR is named alongside LLY and NVO — the Chinese small-molecule GLP-1 competitor being framed as validation (not threat) is the correct read of a sector where multiple asset winners exist.
  • The tape is coiled at mid-range: 47th-percentile 52-week range, 23% above the 50-day moving average, 6% above the 200-day — that's the setup where either the August 6 earnings delivers a specific catalyst update or the coil resolves downward on peer-set volatility.

August 6 earnings will be operational status; the real catalysts are Phase 3 readouts and any strategic-partnership disclosure. This is pure event-driven biotech — a favorable Phase 3 or a named big-pharma partnership reprices the equity to a $100+ range that community bulls have flagged. Position sizing dominates the trade setup, not fundamental analysis.

Agrees with X sentimentThe small bullish crowd (5 posts) is aligned on the peer-set framing versus VKTX/LLY/NVO and the M&A-target thesis — directly supported by the sector context. Small sample but honest.

What to watch: August 6 earnings (operational update), and any Phase 3 readout milestone. A named big-pharma partnership or a specific readout timeline is what would break the coil upward; peer-set volatility is what would break it downward.

On the calendar: 2026-08-06 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-08

Structure Therapeutics is being framed as a next-leg-higher obesity/GLP-1 play. Cantor and Piper Sandler both reiterated Overweight on Viking Therapeutics with GPCR named in the same peer set alongside LLY and NVO, and a Chinese small-molecule GLP-1 competitor is being cross-analyzed as validation of the space rather than a direct threat. Retail voices are more emphatic, calling for a run toward $100 or a buyout given repeated tests of overhead resistance on light volume, though the sample is thin.

Read the AI verdict + X sentiment for $GPCR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing an oral GLP-1 receptor agonist (GSBR-1290) for obesity and type 2 diabetes, with additional GPCR pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $GPCR.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $GPCR

Partial — Clinical-stage biotech developing an oral GLP-1 receptor agonist (GSBR-1290) for obesity and type 2 diabetes, with additional GPCR pipeline; this segment overlaps with the GLP-1 pipeline bifurcation and ADA oral formulation competition but is not the dominant revenue driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.2%YTD
+43.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-19.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-14.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-15.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.35$-0.39+10.3%
Q4 2025Feb 26, 2026$-0.49$-0.35-40.0%
Q3 2025Nov 6, 2025$-0.37$-0.36-2.8%
Q2 2025Aug 6, 2025$-0.36$-0.28-28.6%
Next earningsThu, Aug 6·consensus EPS $-0.39

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.05$14.1M
Q4 FY25$0———$0.60$-65.9M
Q3 FY25$0———$-1.11$-52.6M
Q2 FY25$0———$-1.08$-54.8M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$38.5M$38.5M – $38.5M-$1.44-$1.69 – -$1.269
FY27$50K$50K – $50K-$1.96-$2.49 – -$1.6912
FY28$186.4M$186.4M – $186.4M-$1.61-$2.43 – $1.0910
FY29$539.4M$539.4M – $539.4M-$0.29-$0.29 – -$0.295
FY30$831.6M$831.6M – $831.6M$1.07$1.07 – $1.075

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.44%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+16.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+0.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 54.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-1.575-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 25Xichen LinCHIEF SCIENTIFIC OFFICER7.9K sh—SellApr 14Llc FmrSee Remark 117.5K sh—
+ 21 other (13 awards · 6 inkinds · 1 exempt · 1 conversion) in window

See when $GPCR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
8-KMaterial agreementMay 78-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 8.01: Other event
424B5Prospectus supplement (offering)May 7424B5
AI summary

Structure Therapeutics amended and restated its ATM sales agreement removing the aggregate offering cap, and filed this 424B5 to increase the maximum ATM capacity to $400M aggregate gross; approximately $58.5M (3.04M ADSs) had been sold under the prior agreement, leaving approximately $341.5M remaining capacity. Major ATM upsizing to $400M total; $341.5M remaining represents substantial ongoing dilution potential.

3New insider — initial holdingsApr 233
8-KOfficer or director changeApr 158-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 168-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
+ 10 other (4 13Gs · 1 10-Q · 1 ARS · 1 proxy) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

The Next Phase Of The Obesity Drug Raceyoutube.com·32d agoStructure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)seekingalpha.com·34d agoStructure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·36d agoStructure's experimental obesity pill shows no signs of liver injuryreuters.com·39d agoStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesityglobenewswire.com·40d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$REGN$QTTB$AGEN$MRNA$AURA$SLS$VRTX
Voices on X · last 7 days

No standout posts about $GPCR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport